Teva Pharma Industries Ltd ADR

TEVA

New York Stock Exchange. Currency in USD

8.57 -0.12 ( -1.38% )

Real time prices: December 19

Market Cap.
9.52B
Beta (5Y monthly)
1.25
Price/Earnings
3.21
EPS (TTM)
2.59
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Nov 28, 2017
Volume
9.22M
1y Target Est.
9.70
Day's Range
8.45
-
8.73
52 Week's Range
6.78
-
11.34

Historical Summary

Performance
EPS growth
Share Buybacks

About Teva Pharma Industries Ltd ADR

Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Website
https://www.tevapharm.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
1.11B
Employees
34713
Address
124 Dvora Hanevi?a Street, Tel Aviv, Israel, 6944020
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Latest news

AMD, Nike, Zillow among UBS stock picks with the 'highest conviction' for 2023
AMD, Nike, Zillow among UBS stock picks with the 'highest conviction' for 2023

'Tis the season for 2023 stock picks, and UBS analysts are out with their favorites,...
By MarketWatch - 6 weeks ago

Is Prometheus Biosciences a Good Stock to Buy Right Now?
Is Prometheus Biosciences a Good Stock to Buy Right Now?

This biotech stock just jumped over 180% in a single day, and investors want to...
By The Motley Fool - 7 weeks ago

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version...
By Zacks Investment Research - 7 weeks ago

3 Unparalleled Stocks to Buy That Have Never Been This Cheap
3 Unparalleled Stocks to Buy That Have Never Been This Cheap

These three leading companies are ripe for the picking and may never be this cheap...
By The Motley Fool - 8 weeks ago

4 Analysts Have This to Say About Teva Pharmaceutical Indus
4 Analysts Have This to Say About Teva Pharmaceutical Indus

Teva Pharmaceutical Indus (NYSE:TEVA) has observed the following analyst ratings within the last quarter: Bullish...
By Benzinga - 9 weeks ago

Analyst Ratings for Teva Pharmaceutical Indus
Analyst Ratings for Teva Pharmaceutical Indus

Analysts have provided the following ratings for Teva Pharmaceutical Indus (NYSE:TEVA) within the last quarter:...
By Benzinga - 9 weeks ago

Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box

Barclays raised the price target on Burlington Stores, Inc. (NYSE: BURL) from $164 to $230....
By Benzinga - 9 weeks ago

What 4 Analyst Ratings Have To Say About Teva Pharmaceutical Indus
What 4 Analyst Ratings Have To Say About Teva Pharmaceutical Indus

Teva Pharmaceutical Indus (NYSE:TEVA) has observed the following analyst ratings within the last quarter: Bullish...
By Benzinga - 9 weeks ago